GPR55 and cholangiocarcinoma: Interestingly, not only was the treatment with AEA able to reduce cholangiocarcinoma cell proliferation in vitro and in vivo, but this effect was also observed with another GPR55 agonist, O-1602 (Huang et al., 2011).